| Net income (loss) and comprehensive income (loss) | -178.81M |
| Depreciation and amortization | 3.95M |
| Loss on disposal of assets | |
| Realized gain on sale of short-term securities-available-for-sale | |
| Write-down of short-term securities-available-for-sale | |
| Impairment charge on real estate owned | |
| Stock-based compensation | 23.09M |
| Conversion of interest accrued to common stock | |
| Acquired in-process research and development | |
| Increase (decrease) on warrant valuation | |
| Accounts receivable and other current assets | |
| Net increase in accounts payable, accrued employee compensation, and other liabilities | |
| Net cash used in operating activities | |
| Purchase of property and equipment | -2.43M |
| Patent costs | -1.09M |
| Purchase of marketable securities | |
| Sale of marketable securities | |
| Acquisition costs | |
| Net cash used in investing activities | |
| Proceeds from sale of common stock, warrants, and partnership units, net of offering costs, and exercise of options and warrants | 10.97M |
| Repayments of long-term debt | |
| Buyback of common stock pursuant to rescission offering | |
| Withdrawal of partnership net assets | |
| Issuance of convertible debt | |
| Net cash provided by (used in) financing activities | |
| Increase (decrease) in cash and cash equivalents | 314.84M |
| Beginning of period | 80.3M |
| End of period | 395.14M |
| Cash paid during the year for interest | 1.2M |
| Short-term securities-available-for-sale received in connection with the private offering | |
| Issuance of common stock and warrants in satisfaction of liabilities | |
| Issuance of common stock for building purchase | |
| Assumption of long-term debt for building purchase | |
| Issuance of common stock for Ercole assets | |
| Assumption of liabilities for Ercole assets | |